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Background: It is hypothesized that because of higher mast cell numbers and mediator release, mastocytosis
predisposes patients for systemic immediate-type hypersensitivity reactions to certain drugs including non-steroidal
anti-inflammatory drugs (NSAID).
Objective: To clarify whether patients with NSAID hypersensitivity show increased basal serum tryptase levels as
sign for underlying mast cell disease.
Methods: As part of our allergy work-up, basal serum tryptase levels were determined in all patients with a
diagnosis of NSAID hypersensitivity and the severity of the reaction was graded. Patients with confirmed
IgE-mediated hymenoptera venom allergy served as a comparison group.
Results: Out of 284 patients with NSAID hypersensitivity, 26 were identified with basal serum tryptase > 10.0 ng/mL
(9.2%). In contrast, significantly (P = .004) more hymenoptera venom allergic patients had elevated tryptase >
10.0 ng/mL (83 out of 484; 17.1%). Basal tryptase > 20.0 ng/mL was indicative for severe anaphylaxis only in venom
allergic subjects (29 patients; 4x grade 2 and 25x grade 3 anaphylaxis), but not in NSAID hypersensitive patients
(6 patients; 4x grade 1, 2x grade 2).
Conclusions: In contrast to hymenoptera venom allergy, NSAID hypersensitivity do not seem to be associated with
elevated basal serum tryptase levels and levels > 20 ng/mL were not related to increased severity of the clinical
reaction. This suggests that mastocytosis patients may be treated with NSAID without special precautions.
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Pseudo-allergyBackground
Anaphylaxis is defined as a systemic hypersensitivity re-
action, which can be sub-classified as allergic anaphyl-
axis when the reaction is mediated by an immune
mechanism, or non-allergic anaphylaxis induced by
non-immunologic triggers (formerly called anaphylactoid
reaction) [1]. Non-steroidal anti-inflammatory drugs
(NSAID) are the most common causes of non-allergic
drug-induced systemic hypersensitivity reactions [2]. In
the pathogenesis of non-allergic anaphylactic reactions,
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unless otherwise stated.inhibition of cyclooxygenase 1, up-regulation of endo-
thelial cell-active mediators, and specific enzyme defects
are discussed [3,4].
Mastocytosis comprises a heterogeneous disease spectrum
with increased mast cell burden mainly in skin and bone
marrow. Less frequently, involvement of the gastro-
intestinal tract, lymph nodes, spleen, and liver occur.
Anaphylaxis symptoms may develop due to liberation of
mast cell mediators whereas chronic organ dysfunction
is caused by progressive tissue infiltration with mast
cells. Known non-immunologic trigger factors for liber-
ation of mast cell mediators are specific physical stimuli
(such as skin rubbing, heat or physical exercise) and cer-
tain drugs [5]. While some observations suggest a pos-
sible increase of risk and severity for non-allergicd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cytosis patients, confirmatory data is sparse [6]. Never-
theless, NSAID are still considered as triggering
anaphylactic reactions in patients with mast cell disease,
probably because this group of compounds accounts for
most non-allergic hypersensitivity reactions overall.
Aim of this retrospective analysis was to evaluate the
relevance of basal serum tryptase measurement in pa-
tients with NSAID hypersensitivity reactions using a co-
hort of clinically and diagnostically well-defined patients.
Basal serum tryptase values and grade of anaphylaxis
were compared with a cohort of patients suffering from
hymenoptera venom allergy.
Methods
Patients with NSAID hypersensitivity
From 2004 to 2011, all patients referred to the allergy
clinic of Würzburg with a history of hypersensitivity re-
actions induced by NSAID were subjected to standard-
ized allergy diagnostics including determination of basal
serum tryptase. Written informed consent for allergy
work-up was obtained and the local Ethics Committee
of the Faculty of Medicine, University of Würzburg,
Germany approved data collection and evaluation.
Allergy testing
We performed prick and intradermal tests on the volar
forearm with a series of NSAID, including the culprit
drug as described previously [7-9]. Test procedures and
readings after 15 minutes were performed according to
the EAACI recommendations [10]. In individual cases
allergic or non-allergic hypersensitivity to other con-
comitantly administered drugs and/or other exposed an-
tigens (e.g. natural rubber latex from stoppers, tubes or
gloves) which may have been responsible for the symp-
toms as well, were excluded by skin and provocation
testing. All agents were freshly reconstituted, and
physiological saline solution was used as negative con-
trol. Provocation testing with NSAID was done accord-
ing to published protocols using standardized doses [7].
General principles of our protocol were as follows: (a)
the time interval since the hypersensitivity reaction was
at least 2 weeks; (b) during the entire provocation pro-
cedure the patient was observed and equipment for
emergency treatment was available; (c) the dosage in-
creased stepwise to a normal dose with intervals ofTable 1 Grading system for anaphylaxis (modified from [11])
Grade Sympto
1 (mild): skin and subcutaneous tissue only Generali
2 (moderate): features suggesting respiratory,
cardiovascular and/or gastrointestinal involvement
Dyspnoe
abdomin
3 (severe): hypoxia, hypotension and
neurological compromise
Cyanosis
confusio1hour between the individual doses; (d) strict adherence
to absolute and relative contraindications for drug chal-
lenge tests; (e) prior to provocation testing written in-
formed consent was obtained from each patient.
Hymenoptera venom allergic patients
During 2004 to 2011, basal serum tryptase levels of pa-
tients with anaphylactic IgE-mediated reactions after
bee/wasp stings (diagnosis by positive serum-IgE and/or
skin testing) eligible for venom immunotherapy were de-
termined. This cohort of clinically and diagnostically
well-defined patients served as a comparison group.
Grading of anaphylaxis
The reported hypersensitivity symptoms were classified
according to severity (Table 1) [11]. Grade 1 consists of
cutaneous symptoms such as urticaria and angioedema;
grade 2 (moderate) and 3 (severe anaphylaxis) include
symptoms of the following organ systems: cardiovascular
(hypotension, tachycardia), respiratory (dyspnoea, bronch-
oconstriction), and digestive tract (vomiting, abdominal
pain, incontinence). Only patients with clearly docu-
mented objective symptoms of at least grade 1 anaphylaxis
were included.
Tryptase measurement
For determination of baseline serum tryptase levels (ob-
tained at least 1 week after resolution of the clinical
signs) commercially available ImmunoCAP™ Tryptase
was used, an in-vitro test for the quantitative measure-
ment of both alpha and beta tryptase concentration in
human serum [12].
Diagnosis of mastocytosis
Criteria for classification and diagnosis of mastocytosis
were applied as published in recent consensus papers
[13,14].
Statistical analysis
To compare the group of hymenoptera venom allergic pa-
tients with the group suffering from NSAID hypersensitiv-
ity, the Mann–Whitney test was conducted in case of a
metrically scaled outcome variable. For nominal outcome
variables we used either the Chi-square test or Fisher’s
exact test depending on the number of outcome categor-
ies. All tests were two-tailed and a P value smaller thanms
zed urticaria and/or angioedema (e.g. periorbital oedema, lip oedema)
a, chest or throat tightness, stridor, wheeze, nausea,
al pain, vomiting, tachycardia, dizziness (presyncope)
, hypotension (systolic blood pressure < 90 mm Hg in adults),
n, collapse, loss of consciousness, loss of sphincter control (incontinence)
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was done using SPSS version 21 for Windows (SPSS Inc.,
Chicago, IL).
Results
Patients with NSAID hypersensitivity
284 patients, 203 females and 81 males, presenting with
hypersensitivity symptoms induced by NSAID, were
evaluated (Table 2). The average age at the time of the
reaction was 51 years (ranging from 10 to 89 years).
NSAID were administered orally (n = 249), intravenously
(n = 14), intramuscularly (n = 19) or in form of a sup-
pository (n = 2). 256 patients had experienced NSAID
hypersensitivity within 12 months prior to testing, 22 be-
tween 1 and 5 years, and 6 between 6 and 10 years prior
to testing.
Allergy testing
Definite confirmation of non-allergic NSAID hypersensi-
tivity was achieved by positive provocation testing in all
284 patients with negative NSAID skin tests. The type of
clinical NSAID hypersensitivity was urticaria/angio-
edema in all patients; in 201 exacerbation of theTable 2 Clinical data and tryptase values of patients with NSA
allergy group
NSAID Comp
Number of patients 284
Mean age (range) 51 (10–89)
Male/female 81/203
Severity of anaphylaxis
Grade 1 174 (61.3%)
Grade 2 110 (38.7%)
Grade 3 0 (0.0%)
Application
Oral 249
Intravenous 14
Intramuscular 19
Suppository 2
Basal serum tryptase
Minimum [ng/mL] 0.0
Maximum [ng/mL] 94.8
Mean [ng/mL] 5.9
0.0 to 5.0 ng/mL 166 (58.5%)
> 5.0 to 10.0 ng/mL 92 (32.4%)
> 10.0 ng/mL 26 (9.2%)
> 10.0 to 20.0 ng/mL 20 (7.0%)
> 20.0 to 50.0 ng/mL 5 (1.8%)
> 50.0 ng/mL 1 (0.4%)
P values calculated from the comparison between patients with NSAID hypersensitisymptoms occurred in subjects with underlying chronic
spontaneous urticaria and in the remaining 83 of pa-
tients urticaria/angioedema developed without an obvi-
ous history of chronic urticaria. Therefore, 70.8% of
patients could be classified as NSAID-exacerbated cuta-
neous disease (NECD) and 29.2% as NSAID-induced ur-
ticaria/angioedema (NIUA) as proposed by a recent
position paper [15]. Besides urticaria/angioedema, in 110
patients (38.7%, Table 2) symptoms suggesting respira-
tory, cardiovascular or gastrointestinal involvement such
as dyspnoea, throat tightness, nausea, abdominal pain,
tachycardia or dizziness developed during NSAID provo-
cation testing.Hymenoptera venom allergic patients
Association of hymenoptera venom allergy with ele-
vated basal serum tryptase has recently been shown in
several studies [5,16-18]. Accordingly, of the 484 pa-
tients in the comparison group suffering from hymen-
optera venom allergy, a significant number with
elevated tryptase levels and severe anaphylactic reac-
tions were identified (Table 2).ID hypersensitivity as well as the hymenoptera venom
arison group: hymenoptera venom allergy P values
484 n.a.
47 (7–81) .026
287/197 < .001
< .001
26 (5.4%)
249 (51.4%)
209 (43.2%)
n.a.
n.a.
n.a.
n.a.
n.a.
.004
0.0
148.0
7.8
276 (57.0%)
125 (25.8%)
83 (17.1%)
54 (11.2%)
24 (5.0%)
5 (1.0%)
vity and hymenoptera venom allergy. n.a., not applicable.
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Details of the 6 NSAID hypersensitive patients with
basal serum tryptase levels > 20 ng/mL are shown in
Table 3. Four of these suffered from urticaria/angio-
edema whereas 2 patients experienced moderate (grade
2) anaphylaxis. This was in contrast to the 29 hymenop-
tera venom allergic patients with tryptase levels > 20 ng/
mL, where 25 developed severe (grade 3) anaphylaxis
(Table 4).
Diagnosis of mastocytosis
Diagnosis of indolent systemic mastocytosis could con-
clusively be achieved in 3 NSAID hypersensitive patients
and in 15 hymenoptera venom allergic patients (Table 3,
Table 4). Because of histologically proven skin involve-
ment a preliminary diagnosis of mastocytosis in the skin
according to current guidelines was made in 1 NSAID
hypersensitive and in 3 hymenoptera venom allergic sub-
jects with basal serum tryptase levels > 20 ng/mL [13].
Unfortunately, in several patients listed in Table 3 and
Table 4 not all necessary clinical examinations for final
classification of mastocytosis were performed [13,14].
These patients were labelled as “classification not deter-
mined yet”.
Statistical comparison between patients with NSAID
hypersensitivity and hymenoptera venom allergy
Calculated P values are depicted in Table 2. As expected,
age of patients, male–female ratio and severity of ana-
phylaxis were statistically significantly different, i.e.
venom allergic patients are younger, are predominantly
male, and suffered from more severe anaphylaxis. Com-
pared with NSAID hypersensitive patients, basal serum
tryptase levels were significantly higher in venom allergic
subjects (P = .004).
Discussion
In hymenoptera venom allergic subjects, raised baseline
serum tryptase levels (obtained at least 1 week after
resolution of the clinical signs) have been identified as a
substantial risk factor for more severe anaphylaxis
[5,16-18]. In accordance to these data, our group ofTable 3 Characteristics of patients with NSAID hypersensitivit
Patient Age, sex Drug Application Latency
[minutes]
Anaphyl
#1 54, f Acetylsalicylic acid Oral 15
#2 61, f Acetylsalicylic acid Oral 30
#3 72, f Metamizol Oral 20
#4 54, f Diclofenac Oral 20
#5 37, f Acetylsalicylic acid Oral 30
#6 71, f Diclofenac Oral 10
ISM, indolent systemic mastocytosis. CM, cutaneous mastocytosis. n.d., not determinhymenoptera venom allergic patients included a signifi-
cant number with a history of severe anaphylactic reac-
tions to hymenoptera stings and concomitantly elevated
tryptase levels of > 20 ng/mL.
In contrast to immune-mediated allergy, the most im-
portant triggers of non-allergic drug-induced hypersensi-
tivity are NSAID. The clinical symptoms of these
reactions may closely mimic IgE-mediated mild to moder-
ate anaphylaxis and mast cell degranulation has been
demonstrated in IgE-mediated reactions as well as in non-
allergic drug-induced hypersensitivity [3,19]. Together
with a generally increased risk for anaphylaxis in patients
with mastocytosis [3,4,11], and because of individual cases
reporting about severe non-allergic drug hypersensitivity
reactions in these patients, it has been concluded that
mastocytosis patients may be predisposed for NSAID-
induced reactions [6]. In our clinically well-defined cohort
of patients with non-allergic NSAID hypersensitivity, ele-
vated basal serum tryptase levels were found only in a
small number of cases and elevated tryptase levels seemed
to be not associated with more severe reactions. In con-
trast to hymenoptera venom allergic patients, baseline
serum tryptase levels in our NSAID hypersensitive sub-
jects did not differ from those published in a general adult
population (mean 5.6 ng/mL) [20].
Up to date there have been a limited number of stud-
ies focusing on the association of mastocytosis and non-
allergic drug hypersensitivity. In an Italian study, 7 out
of 86 patients (8.1%) were identified with an elevated
baseline serum tryptase of > 11.4 ng/mL, ranging from
13.2 to 26.9 ng/mL [17]. The incriminated drugs in-
cluded acetylsalicylic acid (2x), β-lactam antibiotics (2x),
chloramphenicol, radio contrast medium, and chlorhexi-
dine, respectively. In this study, only one patient was di-
agnosed with indolent systemic mastocytosis. Another
study identified in a cohort of 83 mastocytosis patients
16 (19.3%) individuals with a history of drug-induced
anaphylaxis. The incriminated drugs in this study were
β-lactam antibiotics (4x), fosfomycin, NSAID (4x), co-
deine, mepivacaine, and rocuronium and in 4 patients
hypersensitivity reactions could not be attributed to a
single identifiable drug [21]. In our cohort of 284 NSAIDy and basal serum tryptase level > 20 ng/mL
axis [grade] Treatment Tryptase [ng/mL] Classification
of Mastocytosis
1 H1-blocker 39.7 ISM
1 No 42.2 ISM
1 No 23.5 CM
1 No 32.7 n.d.
2 H1-blocker, steroids 26.2 n.d.
2 H1-blocker 94.8 ISM
ed yet.
Table 4 Characteristics of patients with hymenoptera venom allergy and basal serum tryptase level > 20 ng/mL
Patient Age, sex Stinging insect Anaphylaxis [grade] Tryptase [ng/mL] Classification of Mastocytosis
#1 54, m Wasp 3 27.2 n.d.
#2 60, m Wasp 3 88.3 ISM
#3 65, f Wasp 3 105.0 ISM
#4 54, m Wasp 3 27.5 n.d.
#5 72, m Wasp 3 29.2 ISM
#6 60, m Wasp 3 20.9 n.d.
#7 62, m Bee 3 23.1 CM
#8 43, f Wasp 3 27.1 CM
#9 35, m Bee 3 25.4 n.d.
#10 41, m Bee 3 40.1 ISM
#11 46, m Wasp 3 41.4 ISM
#12 53, m Wasp 3 98.1 ISM
#13 49, m Wasp 3 21.3 n.d.
#14 56, m Wasp 3 25.4 n.d.
#15 51, f Bee 3 28.6 ISM
#16 46, m Wasp 3 25.2 CM
#17 69, m Wasp 3 26.5 ISM
#18 74, m Wasp 3 34.6 ISM
#19 53, m Bee 3 23.0 n.d.
#20 43, m Wasp 3 25.6 n.d.
#21 40, m Wasp 2 28.6 n.d.
#22 43, m Wasp 3 39.9 ISM
#23 54, f Wasp 3 35.8 ISM
#24 40, m Wasp 3 32.0 ISM
#25 29, m Wasp 2 148.0 ISM
#26 36, m Wasp 3 25.4 n.d.
#27 64, f Wasp 3 32.0 ISM
#28 64, m Wasp 2 20.6 n.d.
#29 31, m Wasp 2 129.0 ISM
ISM, indolent systemic mastocytosis. CM, cutaneous mastocytosis. n.d., not determined yet.
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basal serum tryptase levels of > 10 ng/mL. It was hypoth-
esized that systemic hypersensitivity reactions in patients
with mastocytosis tend to be more severe. We were not
able to confirm this hypothesis because only 2 of 6 pa-
tients with serum tryptase levels of > 20 ng/mL had
moderate (grade 2) anaphylaxis not requiring adrenaline,
while the remaining 4 patients experienced merely
symptoms of urticaria and angioedema.
The pathogenesis of NSAID-induced non-allergic
hypersensitivity is believed to be related to cyclooxgenase
1 inhibition resulting in activation of mediator release
from inflammatory cells in the skin and not to an IgE-
mediated allergy [22]. Although the exact role of mast
cells and histamine is still not clear, a predisposition for
drug-induced non-allergic hypersensitivity has beenpostulated for mastocytosis patients. This resulted in rec-
ommendations to avoid NSAID in patients with con-
firmed mastocytosis. In cases of medical necessity, pre-
treatment with H1-antihistamines and corticosteroids or
graded challenges should be performed. However, our and
the limited data in the literature failed to demonstrate a
high risk for mast cell disease in patients with non-allergic
NSAID hypersensitivity. Furthermore, the severity of
hypersensitivity reactions was not increased in those pa-
tients with elevated basal tryptase levels with or without
confirmed mastocytosis, suggesting that the recommenda-
tion to avoid NSAID may be not necessary.
While the association of mastocytosis and hymenop-
tera venom allergy has been confirmed in several studies,
the role of drugs as triggers for anaphylaxis in patients
with mast cell disease is still unclear. In our patients
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basal tryptase levels appear not to be elevated and in-
creased levels were not associated with a stronger sever-
ity of clinical reactions.
Clinical implications
In patients suffering from NSAID hypersensitivity, deter-
mination of basal serum tryptase is unlikely to identify
patients with elevated levels or mastocytosis and did not
indicate increased reaction severity. This suggests that
mastocytosis patients could be treated with this class of
drugs without special precautions.
Abbreviation
NSAID: Non-steroidal anti-inflammatory drug.
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